Adverse Events and Serological Responses After SARS-CoV-2 Vaccination in Individuals With Inflammatory Bowel Disease.
Am J Gastroenterol
; 118(9): 1693-1697, 2023 09 01.
Article
en En
| MEDLINE
| ID: mdl-37216598
ABSTRACT
INTRODUCTION:
We determined adverse events after 4 doses of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine in those with inflammatory bowel disease (IBD), associations between antibodies and injection site reactions (ISR), and risk of IBD flare.METHODS:
Individuals with IBD were interviewed for adverse events to SARS-CoV-2 vaccine. Multivariable linear regression assessed the association between antibody titers and ISR.RESULTS:
Severe adverse events occurred in 0.03%. ISR were significantly associated with antibody levels after the fourth dose (geometric mean ratio = 2.56; 95% confidence interval 1.18-5.57). No cases of IBD flare occurred.DISCUSSION:
SARS-CoV-2 vaccines are safe for those with IBD. ISR after the fourth dose may indicate increased antibodies.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Enfermedades Inflamatorias del Intestino
/
Vacunas contra la COVID-19
/
COVID-19
Límite:
Humans
Idioma:
En
Revista:
Am J Gastroenterol
Año:
2023
Tipo del documento:
Article
País de afiliación:
Canadá